Investment accelerates global adoption of Noxilizer’s terminal sterilization alternative that is validated, safe, scalable and sustainable for biopharmaceutical and medical device manufacturers
Noxilizer, Inc. (“Noxilizer”), the leader in nitrogen dioxide-based terminal sterilization for biopharmaceutical and medical device products, today announced a growth capital financing of $30 million led by NewVale Capital, a growth equity firm focused on the pharmaceutical services sector.
Noxilizer’s nitrogen dioxide (“NO₂”) sterilization platform plays a pivotal role in addressing the urgent market demand for alternatives to ethylene oxide (“EtO”), with leading pharmaceutical, biotechnology, and medical device companies already relying on Noxilizer to sterilize critical drug-device combination products. This growth financing will expand access to Noxilizer’s NO₂ sterilization platform to meet growing global demand.
“This investment allows us to broaden availability of NO₂ sterilization at a time when manufacturers urgently need validated, commercial-ready alternatives to existing methods,” said Christopher Thatcher, President and Chief Executive Officer of Noxilizer. “We’re proud to provide a platform that is already trusted in commercial-stage products. With NewVale Capital’s support, we are strengthening our foundation to serve our customers at scale, with long-term reliability, especially as EtO contract sterilization providers face increasing remediation mandates and capacity constraints.”
Noxilizer provides biopharmaceutical and medical device manufacturers with a proven commercial-grade sterilization alternative that offers:
- Commercial and Regulatory Validation: Approved by global regulatory authorities and used in marketed biopharmaceutical products
- Safety and Sustainability: Non-carcinogenic with emissions that meet room air quality standards
- Compatibility: Works with sensitive biologics, drug-device combinations, and delivery systems
- Efficiency and Scale: Provides fast cycle times, can be used in-house, and supports supply chain reliability
“Noxilizer represents one of the most viable alternatives to EtO in the market today,” said Todd Holmes, Founder and Managing Partner of NewVale Capital. “The platform has already been adopted by a growing list of leading manufacturers, and we’re excited to support Noxilizer through its next phase of expansion to meet the rising demand for sustainable, next-generation sterilization.”
